trending Market Intelligence /marketintelligence/en/news-insights/trending/dt2uqv92kc75tnqpj96_0w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Tyme brings in former Celgene sales executive as chief commercial officer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Tyme brings in former Celgene sales executive as chief commercial officer

Tyme Technologies Inc. appointed Michele Korfin as its chief commercial officer.

Korfin, who has over 20 years of experience in commercial sales and marketing in the oncology sector, was most recently at Kite Pharma Inc. where she oversaw market access strategy, including payer relations and reimbursement, for Yescarta, the first CAR-T cell therapy approved by the U.S. Food and Drug Administration to treat lymphoma.

Kite was acquired by Gilead Sciences Inc. for $11.9 billion in cash last year.

Korfin has also worked at Celgene Corp., where she spent a decade in various roles, including as head of the company's oncology sales force of over 120 representatives responsible for $650 million in revenue for pancreatic cancer treatment Abraxane.

Tyme Technologies is developing treatments for multiple cancer types.